Invest in

Drug-Patent Cliffs


Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 14.9%
20.1% Dr. Reddy's Laboratories Ltd RDY 27.5%
18.2% Mylan N.V. MYL 8.0%
17.8% Taro Pharmaceutical Industries Ltd. TARO 28.1%
9.0% Abbott Laboratories ABT 1.0%
8.2% The Medicines Company MDCO 13.6%
8.1% Impax Laboratories Inc. IPXL 37.5%
7.4% Akorn Inc. AKRX 7.1%
6.7% Mallinckrodt plc MNK 5.6%
2.3% Lannett Co Inc LCI 46.4%
1.2% Cambrex Corporation CBM 1.7%
1.1% Endo International PLC ENDP 62.3%

Quotes delayed 15 mins. Currently Oct 24, 2016 11:07:43 PM. Fields are marked with -- when data is unavailable.